Hereditary Cancer and Genetic Testing

Risk management for people with inherited BRIP1 mutations

The National Comprehensive Cancer Network (NCCN) provides risk management guidelines for people with BRIP1 mutations. We recommend that you speak with a genetics expert who can look at your personal and family history of cancer and can help you determine the best risk-management plan. You can learn more about risk management options in our section on Screening and Risk Reduction by Cancer Type

People with a BRIP1 mutation may also qualify for clinical trials looking for more effective screening or prevention for cancer.

Ovarian cancer prevention 

The National Comprehensive Cancer Network (NCCN) guidelines recommend that women with a BRIP1 mutation consider risk-reducing salpingo-oophorectomy (removal of their ovaries and fallopian tubes) between the ages of 45-50 or earlier if there is a family history of an earlier ovarian cancer.

Other cancer screening and prevention

There has not been enough research to show a benefit from screening and prevention for other cancers in people who have a BRIP1 mutation. For this reason, experts recommend managing these risks based on family history of cancer. Cancer screening and prevention research studies may be available for people with BRIP1 mutations. 


If you are a person with an BRIP1 mutation making decisions about managing your cancer risk, you can find peer support through the following resources:


Health plan coverage of screening and prevention varies, and deductibles, coinsurance and copays often apply. If you need preventive services and your insurance company denies your claim, your health care provider can help you write an appeal letter, or you can use one of our sample appeal letters. Visit our section on Insurance and Paying for Care: Screening and Prevention for more information.  


The following screening and prevention studies are open to people with a BRIP1 mutation. 

Last updated September 02, 2021